Nasal vestibulitis due to targeted therapies in cancer patients Journal Article
| Authors: | Ruiz, J. N.; Belum, V. R.; Boers-Doets, C. B.; Kamboj, M.; Babady, N. E.; Tang, Y. W.; Valdez, T. A.; Lacouture, M. E. |
| Article Title: | Nasal vestibulitis due to targeted therapies in cancer patients |
| Abstract: | Background and purpose: Cancer patients treated with targeted therapies (e.g., epidermal growth factor receptor inhibitors) are susceptible to dermatologic adverse events (AEs) including secondary skin infections. Whereas infections such as paronychia and cellulitis have been reported, nasal vestibulitis (NV) has not been described with the use of these agents. The aim of our study was to characterize NV in cancer patients treated with targeted therapies. Methods: We utilized a retrospective chart review of cancer patients who had been referred to dermatology and were diagnosed with NV. We recorded data including demographics, referral reason, underlying malignancy, targeted anticancer regimen, NV treatment, and nasal bacterial culture results. Results: One Hundred Fifteen patients were included in the analysis, of which 13 % experienced multiple NV episodes. Skin rash was the most common reason (90 %) for a dermatology referral. The most common underlying malignancies were lung (43 %), breast (19 %), and colorectal (10 %) cancer. Sixty-eight percent of patients had been treated with an EGFRI-based regimen. Nasal cultures were obtained in 60 % of episodes, of which 94 % were positive for one or more organisms. Staphylococcus aureus was the most commonly isolated organism [methicillin-sensitive S. aureus 43 %; methicillin-resistant S. aureus 3 %]. Conclusions: We report the incidence and characteristics of an unreported, yet frequent dermatologic condition in cancer patients treated with targeted therapies. These findings provide the basis for additional studies to describe the incidence, treatment, and consequences of this event. A better understanding of NV would mitigate its impact on patients’ quality of life and risk for additional dermatologic AEs. © 2015, Springer-Verlag Berlin Heidelberg. |
| Keywords: | adult; major clinical study; sorafenib; bevacizumab; erlotinib; sunitinib; cancer combination chemotherapy; cancer patient; follow up; colorectal cancer; drug eruption; breast cancer; lung cancer; smoking; medical record review; retrospective study; cetuximab; cixutumumab; panitumumab; temsirolimus; electronic medical record; antibiotic resistance; comorbidity; erythema; targeted therapy; methicillin resistant staphylococcus aureus; trastuzumab; microbiology; doxycycline; bacterium culture; pseudomonic acid; epistaxis; everolimus; lapatinib; diseases; epidermal growth factor receptor kinase inhibitor; neratinib; pertuzumab; xerosis; adverse effects; seasonal variation; molecularly targeted therapy; pustule; clindamycin; chlorhexidine gluconate; minimum inhibitory concentration; nose; erosion; selumetinib; vemurafenib; staphylococcal skin infections; nose disease; dabrafenib; afatinib; dacomitinib; dry nose; pimasertib; adverse drug event; cefadroxil; nasal vestibulitis; human; male; female; priority journal; article; binimetinib; necitumumab; polysporin; retapamulin; voxtalisib; furunculosis; impetigo |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 23 |
| Issue: | 8 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2015-08-01 |
| Start Page: | 2391 |
| End Page: | 2398 |
| Language: | English |
| DOI: | 10.1007/s00520-014-2580-x |
| PROVIDER: | scopus |
| PUBMED: | 25876156 |
| PMCID: | PMC4536911 |
| DOI/URL: | |
| Notes: | Export Date: 3 August 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work